Bruker Launches Transformative neofleX™ MALDI-TOF System for Spatial Biology Mass Spec Imaging (MSI) Applications
- neofleX is a versatile, high-performance, and easy-to-use multiomics MSI system for biopharma, translational and clinical researchers
- neofleX Imaging Profiler MALDI-TOF/TOF with proprietary smartbeam 3D laser
- neofleX and MALDI HiPLEX-IHC technology enable protein tissue imaging
- Multiomics MSI correlation of targeted proteins with glycans, metabolites, lipids, endogenous peptides, and now also mid-plex mRNA/DNA-ISH
- More insights per pixel with new SCiLS™ Scope software and OME-TIFF output
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240603327426/en/
![neofleX MALDI-TOF System for Spatial Biology Mass Spec Imaging (MSI) Applications (Photo: Business Wire)](https://mms.businesswire.com/media/20240603327426/en/2147738/4/neofleX.jpg)
neofleX MALDI-TOF System for Spatial Biology Mass Spec Imaging (MSI) Applications (Photo: Business Wire)
The neofleX Imaging Profiler MALDI-TOF/TOF mass spectrometer comes standard with Bruker’s proprietary 10 kHz smartbeam 3D laser for true pixel fidelity and with enhanced imaging detectors designed for longitudinal robustness, stability, and reproducibility in linear and reflector modes. neofleX is also available as a TOF/TOF configuration that features a reimagined fragmentation module for significantly improved TOF/TOF sensitivity, speed and sequence coverage.
Created for the unmet needs of moving from discovery imaging to translational and clinical tissue research, neofleX was used by the group of Prof.
In addition to MALDI HiPLEX-IHC MSI immunohistochemistry, neofleX is also compatible with the MALDI-ISH (in situ hybridization) method announced at ASMS 2024 by
The novel neofleX excels at providing more insight per pixel through multiomic spatial biology data from tissue sections that can positively correlate targeted proteins with glycans, metabolites, lipids, endogenous peptides, xenobiotics, and now RNA/DNA. This additional multiomics context provides important adjacency information about cellular states, function, structure, and protein activity for a range of research areas, such as oncology and neurology.
Professor
Multiomic co-localization of lipids and glycans on a tissue section allows to not only localize protein targets using MALDI HiPLEX-IHC, but also assess protein activity and function. A study performed at CeMOS on brain tissues from a transgenic mouse model demonstrated co-localization of amyloid β-42 (Aβ42) protein with a targeted membrane-bound glycosphingolipid (GM3 d36:1), yielding important structural information.
Dr.
The neofleX is compatible with Bruker’s MALDI Imaging software and consumables ecosystems, such as IntelliSlides™ and SCiLS autopilot that simplify sample tracking, preparation, and analysis and require minimal input from users to initiate and process automated mass-spec imaging runs. For ease of collaborations, the neofleX now delivers targeted imaging data via automatically generated OME-TIFF images that can be viewed within the SCiLS environment, or easily exported into custom pipelines or digital pathology systems.
Bruker also announced extension of the SCiLS portfolio with SCiLS Scope 1.0 for collaboration around targeted, multiomic translational workflows developed for neofleX. SCiLSScope software supports OME-TIFF datasets from targeted imaging workflows such as MALDI HiPLEX-IHC. Ion images are visualized by false-color coding of selected channels, and image processing and distance measurements can be accomplished with simple tools.
About
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240603327426/en/
Media
T: +49 (421) 2205-2843
E: Petra.Scheffer@bruker.com
Investor Relations
Sr. Director Investor Relations &
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com
Source: